Prevention of Post-menopausal Bone Loss with 1 Alpha-hydroxy Vitamin D3. A Three-year Prospective Study

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 1992 Dec 1

PMID 1486738

Citations 3

Authors

J M Pouilles

F Tremollieres

C Ribot

Affiliations

Soon will be listed here.

Abstract

An open and controlled prospective study was used to assess the preventive efficiency of 1 alpha-hydroxy vitamin D3 (1 alpha (OH) Vit. D3) on post-menopausal vertebral bone loss. Of the 36 patients included in the study, 25 completed two years of treatment with 1 microgram/day of 1 alpha (OH) Vit. D3 and 500 mg of calcium. The vertebral bone mineral density measured by dual photon absorptiometry did not vary in the treated group, whereas it decreased significantly in the control group at the end of the 2 years. At two years, withdrawal of treatment led to a significant bone loss, whereas bone mass remained stable in a subgroup of patients who underwent a third year of treatment with 1 alpha (OH) Vit. D3. Overall, tolerance was satisfactory. However, urinary calcium increased significantly during treatment and one third of the patients developed hypercalciuria > or = 7.5 mmoles/24 h. No variation in either serum calcium or creatinine levels was noted. These results indicate that 1 alpha (OH) Vit. D3 could be useful in preventing post-menopausal bone loss provided it was complemented by regular monitoring of urinary calcium excretion.

Citing Articles

Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Brandi M Clin Cases Miner Bone Metab. 2012; 7(3):243-50.

PMID: 22460535 PMC: 3213838.

Treatment of osteoporosis with vitamin D.

Kanis J, McCloskey E, de Takats D, Bernard J, Zhang D Osteoporos Int. 1997; 7 Suppl 3:S140-6.

PMID: 9536320 DOI: 10.1007/BF03194360.

Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview.

Kaufman J Clin Rheumatol. 1995; 14 Suppl 3:9-13.

PMID: 8846661 DOI: 10.1007/BF02210681.

References

Aloia J, Vaswani A, Yeh J, Ellis K, Yasumura S, Cohn S . Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med. 1988; 84(3 Pt 1):401-8. DOI: 10.1016/0002-9343(88)90259-8. View

Falch J, Oftebro H, Haug E . Early postmenopausal bone loss is not associated with a decrease in circulating levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, or vitamin D-binding protein. J Clin Endocrinol Metab. 1987; 64(4):836-41. DOI: 10.1210/jcem-64-4-836. View

Riggs B, Melton 3rd L . Involutional osteoporosis. N Engl J Med. 1986; 314(26):1676-86. DOI: 10.1056/NEJM198606263142605. View

Gallagher J, Riggs B . Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism. 1990; 39(4 Suppl 1):30-4. DOI: 10.1016/0026-0495(90)90269-i. View

Geusens P, Dequeker J, Nijs J, Verstraeten A, Bramm E . Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone. Calcif Tissue Int. 1991; 48(2):127-37. DOI: 10.1007/BF02555877. View

Fujita T . Studies of osteoporosis in Japan. Metabolism. 1990; 39(4 Suppl 1):39-42. DOI: 10.1016/0026-0495(90)90271-d. View

Christiansen C, Christensen M, RODBRO P, Hagen C, TRANSBOL I . Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest. 1981; 11(4):305-9. DOI: 10.1111/j.1365-2362.1981.tb02121.x. View

Hartwell D, Riis B, Christiansen C . Changes in vitamin D metabolism during natural and medical menopause. J Clin Endocrinol Metab. 1990; 71(1):127-32. DOI: 10.1210/jcem-71-1-127. View

Geusens P, Vanderschueren D, Verstraeten A, Dequeker J, Devos P, Bouillon R . Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. Calcif Tissue Int. 1991; 49(3):168-73. DOI: 10.1007/BF02556112. View

10.

Nordin B, Horsman A, Crilly R, Marshall D, Simpson M . Treatment of spinal osteoporosis in postmenopausal women. Br Med J. 1980; 280(6212):451-4. PMC: 1600447. DOI: 10.1136/bmj.280.6212.451. View

11.

Epstein S, Bryce G, HINMAN J, MILLER O, Riggs B, Hui S . The influence of age on bone mineral regulating hormones. Bone. 1986; 7(6):421-5. DOI: 10.1016/8756-3282(86)90001-3. View

12.

Raisz L . Direct effects of vitamin D and its metabolites on skeletal tissue. Clin Endocrinol Metab. 1980; 9(1):27-41. DOI: 10.1016/s0300-595x(80)80019-3. View

13.

Malluche H, Faugere M . Role of calcitriol in the management of osteoporosis. Metabolism. 1990; 39(4 Suppl 1):24-6. DOI: 10.1016/0026-0495(90)90267-g. View

14.

Sorensen O, Andersen R, Christensen M, Friis T, Hjorth L, Jorgensen F . Treatment of senile osteoporosis with 1alpha-hydroxyvitamin D3. Clin Endocrinol (Oxf). 1977; 7 Suppl:169s-175s. DOI: 10.1111/j.1365-2265.1977.tb03378.x. View

15.

Drezner M, Nesbitt T . Role of calcitriol in prevention of osteoporosis: Part I. Metabolism. 1990; 39(4 Suppl 1):18-23. DOI: 10.1016/0026-0495(90)90266-f. View

16.

Orimo H, Shiraki M, Hayashi T, Nakamura T . Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner. 1987; 3(1):47-52. View

17.

Riis B, Thomsen K, Christiansen C . Does 24R,25(OH)2-vitamin D3 prevent postmenopausal bone loss?. Calcif Tissue Int. 1986; 39(3):128-32. DOI: 10.1007/BF02555107. View

18.

Gallagher J, Goldgar D . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990; 113(9):649-55. DOI: 10.7326/0003-4819-113-9-649. View

19.

Pouilles J, Tremollieres F, LOUVET J, Fournie B, Morlock G, Ribot C . Sensitivity of dual-photon absorptiometry in spinal osteoporosis. Calcif Tissue Int. 1988; 43(6):329-34. DOI: 10.1007/BF02553274. View

20.

Marshall D, Nordin B . The effect of 1alpha-hydroxyvitamin D3 with and without oestrogens on calcium balance in post-menopausal women. Clin Endocrinol (Oxf). 1977; 7 Suppl:159s-168s. DOI: 10.1111/j.1365-2265.1977.tb03377.x. View